PRMT5 and non-small cell lung carcinoma: Given the histological diversity within MTAP-loss NSCLC, the potential of PRMT5 and MAT2A inhibitors for future treatment, regardless of disease stage, validates the need for further evaluation of MTAP loss as a pathway to innovative therapies in NSCLC.